Despite decades of stigma and legal barriers, recent years have brought a profound shift in attitudes towards psychedelics. Driven by scientific inquiry and a growing recognition of their potential therapeutic benefits, the benefits of psychedelics are being explored. In this blog post, we explore the impact of an unexpected catalyst driving progress in psychedelics research–
Psilocybin’s therapeutic renaissance Once relegated to the realm of recreational drug use, psilocybin is now at the forefront of a discussion on the potential therapeutic benefits of psychedelics. Arizona is the latest state to take up the discourse: its proposed Senate Bill 1570 (SB 1570) would establish licensed psychedelic-assisted therapy centers, and advance scientific research
Should private equity be involved in health care? If so, in what types of settings? And to what extent? These are baseline considerations around a broad concept referred to as “corporate practice of medicine” (“CPOM”) that state legislatures, agencies, medical licensing boards, courts and attorneys general and grappled with for over a century. The Oregon
We are pleased to welcome five outstanding cannabis attorneys to our Washington and California offices. Aaron Pelley, Kristin Westphal, Karen Albence, Aaron John, and Elijah Hartman have joined our law firm from Cultiva Law Group. They will continue to focus on representing cannabis, hemp, and psychedelics-related businesses. Their clients include business owners and operators, investors,
We are pleased to announce the addition of five outstanding cannabis attorneys to our Washington and California offices. Aaron Pelley, Kristin Westphal, Karen Albence, Aaron John, and Elijah Hartman have joined our law firm from Cultiva Law Group. They will continue to focus on representing cannabis, hemp, and psychedelics-related businesses. Their clients include business owners
Every election cycle, we grade the many of the presidential candidates based on their track record with cannabis (here’s our summary of 2020’s main candidates). We kicked off 2024 with our analysis of incumbent President Joe Biden (Grade C), and followed up with Republican challenger Ron DeSantis (Grade C+), who recently dropped out of the
California recently failed at least twice in passing sweeping statewide psychedelic decriminalization bills: a) SB-58, which Governor Gavin Newsom vetoed last year, and b) SB-519, which didn’t garner enough support in the assembly the year before. It’s now trying something much more modest – convening a workgroup to study psychedelic assisted therapy. The bill at
It’s hard to believe that we are wrapping up the first year of the Oregon Psilocybin Services (OPS) program. Final rules were released at this time last year, following a protracted, two-year development period. The application window for licenses opened timely on January 2, 2023, and the Oregon Health Authority (OHA) continues to administer this
A few months ago, I wrote a post entitled “Making Money in the Psychedelics Industry Will be Harder than Cannabis.” The post was focused mostly on hardships that state-legal psilocybin businesses will face in places like Oregon and Colorado, where I think the deck is heavily stacked against them. Today I want to examine a
Perhaps inevitably, lawmakers introduced a very skinny bill last week to protect states that legalize psilocybin from federal intervention. Specifically, it requires that: [n]o Federal funds may be used to prevent any State or unit of local government from implementing such State’s or unit of local government’s own laws that authorize the use, distribution, sale,
